DK0973501T3 - Vandig suspension til nasal indgivelse af loteprednol - Google Patents

Vandig suspension til nasal indgivelse af loteprednol

Info

Publication number
DK0973501T3
DK0973501T3 DK98900360T DK98900360T DK0973501T3 DK 0973501 T3 DK0973501 T3 DK 0973501T3 DK 98900360 T DK98900360 T DK 98900360T DK 98900360 T DK98900360 T DK 98900360T DK 0973501 T3 DK0973501 T3 DK 0973501T3
Authority
DK
Denmark
Prior art keywords
loteprednol
aqueous suspension
nasal administration
nasal
administration
Prior art date
Application number
DK98900360T
Other languages
Danish (da)
English (en)
Inventor
Koji Doi
Original Assignee
Senju Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharma Co filed Critical Senju Pharma Co
Application granted granted Critical
Publication of DK0973501T3 publication Critical patent/DK0973501T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
DK98900360T 1997-01-16 1998-01-14 Vandig suspension til nasal indgivelse af loteprednol DK0973501T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP1966497 1997-01-16
PCT/JP1998/000108 WO1998031343A2 (en) 1997-01-16 1998-01-14 Aqueous suspension for nasal administration of loteprednol

Publications (1)

Publication Number Publication Date
DK0973501T3 true DK0973501T3 (da) 2004-01-19

Family

ID=12005518

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98900360T DK0973501T3 (da) 1997-01-16 1998-01-14 Vandig suspension til nasal indgivelse af loteprednol

Country Status (32)

Country Link
US (1) US6368616B1 (lt)
EP (1) EP0973501B1 (lt)
KR (1) KR100471708B1 (lt)
CN (1) CN1126535C (lt)
AR (1) AR011773A1 (lt)
AT (1) ATE249205T1 (lt)
AU (1) AU730953C (lt)
BR (1) BR9806771A (lt)
CA (1) CA2278025C (lt)
CZ (1) CZ294919B6 (lt)
DE (1) DE69818026T2 (lt)
DK (1) DK0973501T3 (lt)
EA (1) EA001775B1 (lt)
ES (1) ES2206880T3 (lt)
HU (1) HU226613B1 (lt)
ID (1) ID21892A (lt)
IL (1) IL130979A0 (lt)
LT (1) LT4677B (lt)
LV (1) LV12449B (lt)
MX (1) MXPA99006628A (lt)
NO (1) NO324619B1 (lt)
NZ (2) NZ336990A (lt)
PL (1) PL190753B1 (lt)
PT (1) PT973501E (lt)
RS (1) RS49701B (lt)
SI (1) SI20057A (lt)
SK (1) SK283164B6 (lt)
TR (1) TR199901663T2 (lt)
TW (1) TW503113B (lt)
UA (1) UA52722C2 (lt)
WO (1) WO1998031343A2 (lt)
ZA (1) ZA98303B (lt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI243687B (en) 1998-04-21 2005-11-21 Teijin Ltd Pharmaceutical composition for application to mucosa
AU762145C (en) 1998-08-26 2005-03-17 Teijin Limited Powdery pernasal compositions
DE19947235A1 (de) * 1999-09-30 2001-04-05 Asta Medica Ag Neue Kombination von Loteprednol und beta¶2¶-Adrenorezeptor-Agonisten
AR026073A1 (es) 1999-10-20 2002-12-26 Nycomed Gmbh Composicion farmaceutica acuosa que contiene ciclesonida
US6565832B1 (en) * 2000-01-31 2003-05-20 Schering-Plough Healthcare Products, Inc. Spray composition with reduced dripping
TWI277418B (en) * 2001-06-18 2007-04-01 Noven Pharma Enhanced drug delivery in transdermal systems
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US9808471B2 (en) * 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US7811606B2 (en) * 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US8912174B2 (en) * 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US7419971B2 (en) * 2003-06-19 2008-09-02 Bodor Nicholas S Enhancement of activity and/or duration of action of selected anti-inflammatory steroids for topical or other local application
MXPA05013898A (es) * 2003-06-19 2006-05-25 Nicholas S Bodor Mejoramiento de la actividad y/o duracion de la accion de esteroides antiinflamatorios suaves para la aplicacion topica u otra aplicacion local.
US20050095205A1 (en) * 2003-10-31 2005-05-05 Ramesh Krishnamoorthy Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
MXPA06010849A (es) 2004-03-25 2007-03-08 Bausch & Lomb Uso de loteprednol etabonato para el tratamiento del ojo seco.
US20070099883A1 (en) * 2005-10-07 2007-05-03 Cheryl Lynn Calis Anhydrous mometasone furoate formulation
WO2007058935A2 (en) * 2005-11-14 2007-05-24 Bausch & Lomb Incorporated Ophthalmic composition for dry eye therapy
US7691811B2 (en) * 2006-05-25 2010-04-06 Bodor Nicholas S Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye
US7687484B2 (en) * 2006-05-25 2010-03-30 Bodor Nicholas S Transporter enhanced corticosteroid activity
WO2012119261A1 (en) * 2011-03-10 2012-09-13 Biocia Inc. Enhanced artificial mucus composition comprising hyaluronan for the treatment of rhinitis
EP2758031A1 (en) 2011-09-22 2014-07-30 Bausch & Lomb Incorporated Ophthalmic gel compositions
HUE066356T2 (hu) 2017-08-24 2024-07-28 Novo Nordisk As GLP-1 készítmények és alkalmazásaik
PE20221575A1 (es) 2020-02-18 2022-10-06 Novo Nordisk As Formulaciones farmaceuticas

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5540930A (en) 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
EP0709099A3 (en) 1994-09-28 1996-07-24 Senju Pharma Co Aqueous suspension for nasal administration containing cyclodextrin
KR100508227B1 (ko) 1997-03-14 2006-03-23 센주 세이야꾸 가부시키가이샤 로테프레드놀에타보네이트수성현탁액

Also Published As

Publication number Publication date
PL334614A1 (en) 2000-03-13
US6368616B1 (en) 2002-04-09
LV12449A (lv) 2000-04-20
SK283164B6 (sk) 2003-03-04
EA001775B1 (ru) 2001-08-27
NO324619B1 (no) 2007-11-26
TW503113B (en) 2002-09-21
CA2278025C (en) 2005-09-06
KR100471708B1 (ko) 2005-03-07
KR20000070214A (ko) 2000-11-25
RS49701B (sr) 2007-12-31
NO993453L (no) 1999-07-13
IL130979A0 (en) 2001-01-28
EP0973501B1 (en) 2003-09-10
HUP0002473A2 (hu) 2000-12-28
HU226613B1 (en) 2009-04-28
NZ336990A (en) 2001-03-30
AU730953B2 (en) 2001-03-22
ES2206880T3 (es) 2004-05-16
WO1998031343A2 (en) 1998-07-23
DE69818026D1 (de) 2003-10-16
LT99100A (lt) 2000-02-25
UA52722C2 (uk) 2003-01-15
BR9806771A (pt) 2000-05-16
AU730953C (en) 2002-02-07
CZ294919B6 (cs) 2005-04-13
YU36199A (sh) 2002-09-19
HUP0002473A3 (en) 2001-01-29
AU5495298A (en) 1998-08-07
ATE249205T1 (de) 2003-09-15
AR011773A1 (es) 2000-09-13
ZA98303B (en) 1998-07-20
CN1126535C (zh) 2003-11-05
LV12449B (en) 2000-09-20
PL190753B1 (pl) 2006-01-31
NO993453D0 (no) 1999-07-13
NZ509908A (en) 2004-12-24
SI20057A (sl) 2000-04-30
HK1026138A1 (en) 2000-12-08
CZ237499A3 (cs) 2000-01-12
WO1998031343A3 (en) 1998-09-17
MXPA99006628A (es) 2005-01-10
CN1250370A (zh) 2000-04-12
DE69818026T2 (de) 2004-07-08
EP0973501A2 (en) 2000-01-26
CA2278025A1 (en) 1998-07-23
LT4677B (lt) 2000-07-25
ID21892A (id) 1999-08-05
SK94899A3 (en) 2000-05-16
TR199901663T2 (xx) 1999-09-21
EA199900659A1 (ru) 2000-02-28
PT973501E (pt) 2004-02-27

Similar Documents

Publication Publication Date Title
DE69831421D1 (de) Zusammensetzungen zur nasalen verabreichung
ATE249205T1 (de) Wässrige suspension zur nasalen verabreichung von loteprednol
FR2771012B1 (fr) Pulverisateur nasal
DE69624405D1 (de) Nasenmaske
NO20003161D0 (no) Blandinger for nasal administrasjon av kannabinoider
DE60028845D1 (de) Nasale Beatmungsmaske
DK0954282T3 (da) Fremstilling af partikler til inhalation
ID25629A (id) AMINA BISIKLIK (Pecahan dari P-961362)
DE69819387D1 (de) Kehlkopfmaske
DE69815569D1 (de) Kehlkopfmaske
DK1129741T3 (da) Forstövningsindretning til inhalator
IS5245A (is) Lyfjablanda úr ómeprasól
ATE213142T1 (de) Nasaler dilatator
DE69816858D1 (de) Beatmungssystem
IT1284049B1 (it) Medicamento per somministrazione nasale
NO962103D0 (no) Nasal-applikator
IT1295352B1 (it) Apparecchio per doccia nasale micronizzata
CY2012029I2 (el) Nεα μορφη της 5-ομεπραζολης
EE9900403A (et) Inhalaator
AU144045S (en) Nasal mask
DE69816736D1 (de) Nasale Inhaliervorrichtung
NO985936L (no) Nasal administrasjon av desmopressin
AU144044S (en) Nasal mask
ATE289478T1 (de) Ektoparasitizide wässrige suspensionsformulierungen von spinosynen
EP0975363A4 (en) Attenuated respiratory syncytial virus